A lipidated form of the extracellular domain of influenza M2 protein as a self-adjuvanting vaccine candidate

Zeng, Weiguang; Tan, Andrew M.; Horrocks, Kylie J.; Jackson, David C.

doi:10.1016/j.vaccine.2015.05.053

Cited by 17 publications

(17 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…80 For nanoparticle peptide-based vaccine delivery, lipids are usually used as adjuvanting moieties ( e.g. LCP, 81 Pam2Cys 82 ) and/or hydrophobic cores which allow the self-assembly of peptide epitopes conjugated to them. Self-assembled lipid–peptide conjugates have shown the ability to induce both humoral and cellular immune responses.…”

Section: Nano and Micro-technology In Vaccinesmentioning

confidence: 99%

Peptide-based synthetic vaccines

2016

View full text Add to dashboard Cite

show abstract

Section: Nano and Micro-technology In Vaccinesmentioning

confidence: 99%

Peptide-based synthetic vaccines

2016

View full text Add to dashboard Cite

show abstract

“…With regard to the memory immune response, increased diversity is an important concept for vaccine design. While OAS is harnessed by many universal influenza vaccine strategies (2021222324), OAS-mediated generation of cross-reactive, non-neutralizing antibodies against pathogens such as dengue virus can be a cause of enhanced disease severity after the second infection, which represents a hurdle for vaccine development (22526). …”

Section: Mechanism Of Original Antigenic Sinmentioning

confidence: 99%

“…3); the potential for this repertoire to contribute to adverse outcomes during influenza virus infection has not been adequately studied. Universal vaccine approaches have yielded promising results against influenza in animal models (20222324). However, animal models cannot appropriately and exhaustively model the history of vaccination and infection in humans.…”

Section: Original Antigenic Sin and Influenza Virus Immunity: 'Good' mentioning

confidence: 99%

Original Antigenic Sin Response to RNA Viruses and Antiviral Immunity

et al. 2016

View full text Add to dashboard Cite

The human immune system has evolved to fight against foreign pathogens. It plays a central role in the body's defense mechanism. However, the immune memory geared to fight off a previously recognized pathogen, tends to remember an original form of the pathogen when a variant form subsequently invades. This has been termed 'original antigenic sin'. This adverse immunological effect can alter vaccine effectiveness and sometimes cause enhanced pathogenicity or additional inflammatory responses, according to the type of pathogen and the circumstances of infection. Here we aim to give a simplified conceptual understanding of virus infection and original antigenic sin by comparing and contrasting the two examples of recurring infections such as influenza and dengue viruses in humans.

show abstract

“…LPBVs consist of a polypeptide sequence with a PRR-activating, N-terminal diacyl or triacyl lipid attachment (79). Incorporation of target epitopes using chimeric and conjugate approaches have been demonstrated in LPBVs targeting tuberculosis (TB), human papilloma virus, hepatitis C virus, influenza A virus, human immunodeficiency virus (HIV), and cancer (80)(81)(82)(83)(84)(85). Generally, augmentation of immunogenicity has been reported in these studies, though it is important to note that prophylactic efficacy of the TB vaccine and therapeutic efficacy of the HIV vaccine was not observed (81,84).…”

Section: Genetic Fusion Of Pamp To Pbvmentioning

confidence: 99%

Designs of Antigen Structure and Composition for Improved Protein-Based Vaccine Efficacy

et al. 2020

View full text Add to dashboard Cite

Today, vaccinologists have come to understand that the hallmark of any protective immune response is the antigen. However, it is not the whole antigen that dictates the immune response, but rather the various parts comprising the whole that are capable of influencing immunogenicity. Protein-based antigens hold particular importance within this structural approach to understanding immunity because, though different molecules can serve as antigens, only proteins are capable of inducing both cellular and humoral immunity. This fact, coupled with the versatility and customizability of proteins when considering vaccine design applications, makes protein-based vaccines (PBVs) one of today's most promising technologies for artificially inducing immunity. In this review, we follow the development of PBV technologies through time and discuss the antigen-specific receptors that are most critical to any immune response: pattern recognition receptors, B cell receptors, and T cell receptors. Knowledge of these receptors and their ligands has become exceptionally valuable in the field of vaccinology, where today it is possible to make drastic modifications to PBV structure, from primary to quaternary, in order to promote recognition of target epitopes, potentiate vaccine immunogenicity, and prevent antigen-associated complications. Additionally, these modifications have made it possible to control immune responses by modulating stability and targeting PBV to key immune cells. Consequently, careful consideration should be given to protein structure when designing PBVs in the future in order to potentiate PBV efficacy.

show abstract

A lipidated form of the extracellular domain of influenza M2 protein as a self-adjuvanting vaccine candidate

Cited by 17 publications

References 51 publications

Peptide-based synthetic vaccines

Peptide-based synthetic vaccines

Original Antigenic Sin Response to RNA Viruses and Antiviral Immunity

Designs of Antigen Structure and Composition for Improved Protein-Based Vaccine Efficacy

Contact Info

Product

Resources

About